In 2003, Al‐Hajj and colleagues first found that breast cancer can be derived from BCSCs, and they also identified the surface markers of BCSCs to be CD44+/CD24−.4 Accumulating evidence has indicated that BCSCs are the major cause for metastasis, drug resistance and tumour recurrence. This evidence concerns the gene CD44 and breast carcinoma.